AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...

Do they really matter, though? Let's take a look at what these Wall Street heavyweights have to say about Astrazeneca (AZN) before we discuss the reliability of brokerage recommendations and how ...

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s ...

Tagrisso (osimertinib) as monotherapy and as the backbone for novel combinations across stages and settings of epidermal ...

AstraZeneca declined to comment without detailed clinical data on claims by Chinese makers of a competing experimental lung cancer drug.

AstraZeneca AZN-0.32%decrease; red down pointing triangle plans to invest $2.5 billion in China over five years to build a research-and-development center and strike deals with local biotechnology ...

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

Bạch Mai Hospital and AstraZeneca signed a cooperation agreement on expanding collaboration in scientific research, medical ...

British-Swedish multinational pharmaceutical and biotechnology company AstraZenica on Monday announced the acquisition of ...